Thus, harnessed NKp30+CD8+ T cells might exert superior effector potential to targets with low expression of MHC-class I. Moreover, the fact that NKp30+CD8+ T cell population also co-express inhibitory NK receptors, such as KIRs,23 increases the specificity toward tumor cells and may enhance their safety for adoptive transfer therapies. This evidence concerns the gene NCR3 and neoplasm.